A.I. BURNASYAN FMBC CLINICAL BULLETIN

ISSN 2782-6430 (print)

State Research Center −Burnasyan Federal Medical Biophysical
Center of Federal Medical Biological Agency

The journal is published in Russian.
Format – A4.
The periodicity of the journal is 4 times a year.

Issue №3 2025 год

more

A.I. Burnasyan  FMBC clinical bulletin. 2025 № 3

A.I. Abdullaeva, Ur.D. Udalov, I.S. Makhneva, D.Yu. Akopov, V.N. Olesova

Efficiency of Using the Mitochondrial-Targetted Drug Aicar in the Complex Treatment
 of Patients with Chronic Periodontitis

International Office, State Research Center – Burnasyan Federal Medical Biophysical Center
of Federal Medical Biological Agency, Moscow, Russiа

Contact person: Abdullaevav Al’bina Issupovna: albi.95@mail.ru

Abstract
Background: current research indicates that mitochondrial dysfunction is involved in the pathogenesis and progression of periodontitis by inducing oxidative stress and inflammatory responses. In this regard, research on a mitochondrial-targeted therapeutic approach to a number of inflammatory diseases of the oral cavity, including periodontitis, is currently becoming relevant.

Aim: evaluate the dynamics of clinical and index indicators of periodontal condition in patients during the treatment of chronic generalized periodontitis (CGP) using the mitochondrial stimulator Aicar.

Materials and methods: the examination of 88 patients with periodontitis was carried out according to a number of parameters: clinical indicators were determined – edema (in %), hyperemia (%), bleeding (%), as well as index indicators – OHI-S – simplified index of oral hygiene (Oral Hygiene Indices – Simplified), PI – periodontitis intensity (periodontal index), SBI – gingival sulcus bleeding index, papillary-marginal-alveolar index (PMA). Clinical and index indicators of the periodontal condition in patients were determined before and after 7 and 14 days, as well as 3 and 6 months after treatment. Patients were divided into the following groups: Group I – Metrogyl for 7 days; Group II – Metrogyl for 7 days + simultaneously Aicar orally for 7 days; Group III – Metrogyl 7 days + continuation of 7 days of Aicar locally; Group IV – Metrogyl 7 days + simultaneously Aicar orally for 7 days + continuation of Aicar locally for 7 days.

Results: it was shown that after 7 days of treatment with Metrogyl (Group I), the detection of clinical signs of inflammation (swelling, hyperemia and bleeding of the gums) decreased to 18.2%, 20.1%, 28.4%, respectively. Moreover, the decrease was recorded to a greater extent when using Metrogyl in combination with Aicar – in Group II – 5.2%, 10.1%, 15.3% (p < 0.05); in Group III – 4.7%, 8.7%, 14.1% (p < 0.05); in Group IV – 2.7%, 6.5%, 11.7% (p < 0.05). A similar trend in patients was also observed when determining periodontal indices.

Conclusions: based on clinical observations, it was found that the combined use of Metrogyl and Aicar was more effective in treating periodontitis than in the group of patients who were treated with Metrogyl alone. Thus, the use of traditional drugs in combination with mitochondria-targeted compounds that reduce oxidative stress may serve as a new therapeutic approach to various periodontal tissue diseases.

Keywords: chronic generalized periodontitis, patients, Metrogyl, Aiсar, clinical and index indicators

For citation: Abdullaeva AI, Udalov UrD, Makhneva IS, Akopov DYu, Olesova VN. Efficiency of Using the Mitochondrial-Targetted Drug Aicar in the Complex Treatment of Patients with Chronic Periodontitis. A.I. Burnasyan Federal Medical Biophysical Center Clinical Bulletin. 2025.3:09-13. (In Russian) DOI: 10.33266/2782-6430-2025-3-09-13

 

REFERENCES

  1. Herrera D., Matesanz P., Martín C., et al. Adjunctive Effect of Locally Delivered Antimicrobials in Periodontitis Therapy: A Systematic Review and Meta-Analysis. J Clin Periodontol. 2020;47:239-256. doi:10.1111/jcpe.13230.
  2. Korniichuk O., Humeniuk V., Isakova O., et al. Analysis of the Effectiveness of Periodontitis Treatment Using Antimicrobial Agents. Int J Stats Med Res. 2023;12:257-265. doi:10.6000/1929-6029.2023.12.30.
  3. Farhad S.Z., Karbalaeihasanesfahani A., Dadgar E., et al. The Role of Periodontitis in Cancer Development, with a Focus on Oral Cancers. Mol Biol Rep. 2024;51:814. doi:10.1007/s11033-024-09737-6.
  4. Dong Z., Wu L., Hong H. Mitochondrial Dysfunction in the Pathogenesis and Treatment of Oral Inflammatory Diseases. Int J Mol Sci. 2023;24:15483. doi:10.3390/ijms242015483.
  5. Jiang W., Wang Y., Cao Z., et al. The Role of Mitochondrial Dysfunction in Periodontitis: from Mechanisms to Therapeutic Strategy. J Periodontal Res. 2023;8;5: 853-863. doi:10.1111/jre.13152.
  6. Deng Y., Xiao J., Ma L., et al. Mitochondrial Dysfunction in Periodontitis and Associated Systemic Diseases: Implications for Pathomechanisms and Therapeutic Strategies. Int J Mol Sci. 2024;25;2:1024. doi:10.3390/ijms25021024.
  7. Абдуллаева А.И., Олесова В.Н., Акопов Д.Ю., Абдуллаев С.А. Выявление структурно-функциональных нарушений в митохондриях тканей пародонта в условиях экспериментальной модели пародонтита // Российский стоматологический журнал. 2024. Т.28. №5. С. 452-461 [Abdullayeva A.I., Olesova V.N., Akopov D.Yu., Abdullayev S.A. Identification of Structural and Functional Disorders in the Mitochondria of Periodontal Tissues in an Experimental Model of Periodontitis. Rossiyskiy Stomatologicheskiy Zhurnal = Russian Dental Journal. 2024;28;5:452-461 (In Russ.)]. doi:10.17816/dent6329372024.
  8. Абдуллаева А.И., Олесова В.Н., Акопов Д.Ю., Олесов Е.Е., Абдуллаев С.А. Роль митохондриальной дисфункции в патогенезе и лечении воспалительных заболеваний полости рта // Российский стоматологический журнал. 2024. Т.28. №6. С. 612-623 [Abdullayeva A.I., Olesova V.N., Akopov D.Yu., Olesov Ye.Ye., Abdullayev S.A. The Role of Mitochondrial Dysfunction in the Pathogenesis and Treatment of Inflammatory Diseases of the Oral Cavity. Rossiyskiy Stomatologicheskiy Zhurnal = Russian Dental Journal. 2024;28;6:612-623 (In Russ.)] doi:10.17816/dent632944.
  9. Rong Z., Tu P., Xu P., et al. The Mitochondrial Response to DNA Damage. Front Cell Dev Biol. 2021;9:669379. doi:10.3389/fcell.2021.669379.
  10. Averbeck D., Rodriguez-Lafrasse C. Role of Mitochondria in Radiation Responses: Epigenetic, Metabolic, and Signaling Impacts. Int J Mol Sci. 2021;22:11047. doi:10.3390/ijms222011047.
  11. Abdullaev S.A., Glukhov S.I., Gaziev A.I. Radioprotective and Radiomitigative Effects of Melatonin in Tissues with Different Proliferative Activity. Antioxidants (Basel). 2021;10;12:1885. doi:10.3390/antiox10121885.
  12. Abdullaev S.A., Glukhov S.I., Gaziev A.I. Melatonin Reduces Radiation Damage to the Spleen and Increases Survival when Administered Before and after the Exposure of Mice to X-Ray Radiation. Biol Bull Russ Acad Sci. 2023;50:3069-3076. doi:10.1134/S1062359023110018.
  13. Upadhayay S., Kumar P. Mitochondrial Targeted Antioxidants as Potential Therapy for Huntington’s Disease. Pharmacol Rep. 2024;76:693-713. doi:10.1007/s43440-024-00619-z.
  14. Tripathi V., Jaiswal P., Assaiya A., et al. Anti-Cancer Effects of 5-Aminoimidazole-4-Carboxamide-1-Beta-d-Ribofuranoside (Aicar) on Triple-Negative Breast Cancer (TNBC) Cells: Mitochondrial Modulation as an Underlying Mechanism. Curr Cancer Drug Targets. 2022;22;3:245-256. doi:10.2174/1568009622666220207101212.
  15. Wu Y., Duan X., Gao Z., et al. Aicar Attenuates Postoperative Abdominal Adhesion Formation by Inhibiting Oxidative Stress and Promoting Mesothelial Cell Repair. PLoS One. 2022;17;9:e0272928. doi:10.1371/journal.pone.0272928.
  16. Абдуллаева А.И., Акопов Д.Ю., Махнева И.С., Каирбеков Р.Д., Абдуллаев С.А. Нарушение и коррекция функций митохондрий в патогенезе различных заболеваний полости рта: Учебное пособие для врачей-стоматологов. М.: ФМБЦ им. А.И. Бурназяна ФМБА России, 2024. 40 с. [Abdullayeva A.I., Akopov D.Yu., Makhneva I.S., Kairbekov R.D., Abdullayev S.A. Narusheniye i Korrektsiya Funktsiy Mitokhondriy v Patogeneze Razlichnykh Zabolevaniy Polosti Rta = Violation and Correction of Mitochondrial Functions in the Pathogenesis of Various Diseases of the Oral Cavity. Textbook for Dentists. Moscow, FMBTS im. A.I. Burnazyana FMBA Rossii Publ., 2024. 40 p. (In Russ.)]. ISBN 978-5-93064-301-5. EDN BGICIU.
  17. Абдуллаева А.И., Олесова В.Н., Акопов Д.Ю., Абдуллаев С.А. Коррекция митохондриальной дисфункции при комбинированном применении препаратов метрогил и аикар в экспериментальной модели пародонтита // Клинический вестник ФМБЦ им. А.И. Бурназяна. 2024. №4. С. 64-70 [Abdullayeva A.I., Olesova V.N., Akopov D.Yu., Abdullayev S.A. Correction of Mitochondrial Dysfunction with the Combined Use of Metrogyl and Aicar in an Experimental Model of Periodontitis. Klinicheskiy Vestnik FMBTS im. A.I. Burnazyana = Clinical Bulletin of the A.I. Burnazyan Federal Medical and Biophysical Center. 2024;4:64-70 (In Russ.)]. doi:10.33266/2782-6430-2024-4-64-70.
  18. Абдуллаева А.И., Акопов Д.Ю., Абдуллаев С.А., Олесова В.Н. Композиции и формы митохондриально-направленных соединений для лечения заболеваний пародонта: Свидетельство о государственной регистрации базы данных №2025620038. Российская Федерация. №2024625805: заявл. 03.12.2024: опубл. 10.01.2025; заявитель ГНЦ ФМБЦ им. А.И. Бурназяна ФМБА России [Abdullayeva A.I., Akopov D.Yu., Abdullayev S.A., Olesova V.N. Kompozitsii i Formy Mitokhondrial’no-Napravlennykh Soyedineniy dlya Lecheniya Zabolevaniy Parodonta = Compositions and Forms of Mitochondria-Targeted Compounds for the Treatment of Periodontal Diseases. Certificate of State Registration of the Database No. 2025620038 Russian Federation. No. 2024625805. Declared. 03.12.2024: Published. 10.01.2025; Applicant State Scientific Center Federal Medical Biophysical Center Named after A.I. Burnazyan of the Federal Medical and Biological Agency of Russia (In Russ.)]. EDN PWWGOL.
  19. Fu L.Y, Yang Y., Tian H., et al. Central Administration of AICAR Attenuates Hypertension Via AMPK/Nrf2 Pathway in the Hypothalamic Paraventricular Nucleus of Hypertensive Rats. Eur J Pharmacol. 2024;974:176373. doi:10.1016/j.ejphar.2024.176373.
  20. Kawashima H., Ozawa Y., Toda E., et al. Neuroprotective and Vision-Protective Effect of Preserving ATP Levels by AMPK Activator. FASEB J. 2020;34;4:5016-5026. doi:10.1096/fj.201902387RR.
  21. Pyla R., Hartney T.J., Segar L. AICAR Promotes Endothelium-Independent Vasorelaxation by Activating AMP-Activated Protein Kinase Via Increased ZMP and Decreased ATP/ADP Ratio in Aortic Smooth Muscle. J Basic Clin Physiol Pharmacol. 2022;33;6:759-768. doi:10.1515/jbcpp-2021-0308.
  22. Sanli T., Steinberg G.R., Singh G., Tsakiridis T. AMP-Activated Protein Kinase (AMPK) beyond Metabolism: a Novel Genomic Stress Sensor Participating in the DNA Damage Response Pathway. Cancer Biol Ther. 2014;15;2:156-169. doi:10.4161/cbt.26726.
  23. Hinkle J.S., Rivera C.N., Vaughan R.A. AICAR Stimulates Mitochondrial Biogenesis and BCAA Catabolic Enzyme Expression in C2C12 Myotubes. Biochimie. 2022;195:77-85. doi:10.1016/j.biochi.2021.11.004.
  24. Dombi E., Mortiboys H., Poulton J. Modulating Mitophagy in Mitochondrial Disease. Curr Med Chem. 2018;25;40:5597-5612. doi: 10.2174/0929867324666170616101741.
  25. Yamano K., Matsuda N., Tanaka K. The Ubiquitin Signal and Autophagy: an Orchestrated Dance Leading to Mitochondrial Degradation. EMBO Rep. 2016;17;3:300-316. doi:10.15252/embr.201541486.

Conflict of interest. The authors declare no conflict of interest. 
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors. 
Article received: 11.04.2025. Accepted for publication: 15.05.2025

© 2025 Scientific journal - "Clinical Bulletin of the FMBС im. A.I. Burnasyan"
Scroll to Top